ISSN 2149-2263 | E-ISSN 2149-2271
pdf
Volume : 25 Issue : 7 Year : 2021
Quick Search



Myocarditis associated with immune checkpoint inhibitors: Practical considerations in diagnosis and management [Anatol J Cardiol]
Anatol J Cardiol. 2020; 24(2): 68-75 | DOI: 10.14744/AnatolJCardiol.2020.79584

Myocarditis associated with immune checkpoint inhibitors: Practical considerations in diagnosis and management

Muhammet Gürdoğan, Kenan Yalta
Department of Cardiology, Faculty of Medicine, Trakya University; Edirne-Turkey

Immune checkpoint inhibitors (ICI) have caused radical changes in the treatment scheme of many types of cancer in the past 10 years. ICIs are
specific monoclonal antibodies that increase T-cell mediated immune response against cancer cells. Despite important advances in cancer
treatment, uncontrolled activation of cytotoxic T cells has brought along many autoimmune clinical side effects, especially acute myocarditis.
Although the incidence of ICI-related myocarditis is about 1%, it is remarkable in terms of mortality rate reaching 46% and demonstrating the
necessity of rapid diagnosis and multidisciplinary approach. The present review aimed to summarize the heterogeneous symptomatology of
ICI-associated myocarditis, clinical presentation ranging from elevated asymptomatic cardiac enzyme levels to cardiogenic shock, prominent
diagnostic value of cardiac magnetic resonance imaging, and current information on the effectiveness of immunosuppressants in therapy.

Keywords: cardiotoxicity, immune checkpoint inhibitor, myocarditis

Muhammet Gürdoğan, Kenan Yalta. Myocarditis associated with immune checkpoint inhibitors: Practical considerations in diagnosis and management. Anatol J Cardiol. 2020; 24(2): 68-75

Corresponding Author: Muhammet Gürdoğan, Türkiye